Cardiff Oncology(US:CRDF)2025-11-06 21:08Financial Performance - The company had approximately $60.6 million in cash, cash equivalents, and short-term investments as of September 30, 2025, with a projected runway into Q1 2027[4][5]. - Total operating expenses for Q3 2025 were approximately $12.1 million, a decrease of $0.7 million from $12.8 million in Q3 2024, primarily due to reduced clinical trial expenses[6]. - Net cash used in operating activities for Q3 2025 was approximately $10.8 million, an increase of $0.3 million from $10.5 million in the same period in 2024[4]. - The net loss attributable to common stockholders for Q3 2025 was $11.3 million, compared to a net loss of $11.9 million in Q3 2024[12]. - The company reported royalty revenues of $120,000 for Q3 2025, down from $165,000 in Q3 2024[12]. - Total assets as of September 30, 2025, were $63.8 million, down from $97.2 million as of December 31, 2024[14]. Clinical Trial Updates - Cardiff Oncology reported a 19% improvement in confirmed objective response rate (ORR) for the 30mg onvansertib cohort compared to the control arm in the ongoing Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC) as of July 8, 2025[2]. - The median progression-free survival (PFS) has not yet been reached, but early PFS data show a trend favoring the 30mg onvansertib arm versus control[3]. - The company expects to provide an update from the ongoing Phase 2 CRDF-004 trial in Q1 2026[3]. Market Opportunity - Onvansertib is positioned to address a significant medical need, with approximately 150,000 new colorectal cancer patients diagnosed annually in the U.S.[2].